Stay updated on GSK2857916 Two Doses in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the GSK2857916 Two Doses in Multiple Myeloma Clinical Trial page.

Latest updates to the GSK2857916 Two Doses in Multiple Myeloma Clinical Trial page
- Check5 days agoChange DetectedA supplementary MedlinePlus Genetics reference related to multiple myeloma was removed from the study page.SummaryDifference0.1%

- Check11 days agoChange DetectedThe ClinicalTrials.gov record for this completed multiple myeloma study is displayed, including its study design, eligibility criteria, outcomes, locations, and supporting documents, in place of the error page.SummaryDifference100%

- Check19 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide NIH notice announces updates to terminology during the transition from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check33 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.1 to v3.7.2; the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to GSK2857916 Two Doses in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2857916 Two Doses in Multiple Myeloma Clinical Trial page.